Mutual of America Capital Management LLC Purchases New Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Mutual of America Capital Management LLC purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 4,995 shares of the company’s stock, valued at approximately $784,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vaughan Nelson Investment Management L.P. raised its stake in shares of TransMedics Group by 24.3% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares during the last quarter. Natixis Advisors LLC grew its holdings in TransMedics Group by 29.8% during the third quarter. Natixis Advisors LLC now owns 78,073 shares of the company’s stock worth $12,258,000 after buying an additional 17,933 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in TransMedics Group by 6.5% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 44,893 shares of the company’s stock valued at $7,048,000 after buying an additional 2,748 shares during the last quarter. Victory Capital Management Inc. lifted its stake in TransMedics Group by 11.3% during the 3rd quarter. Victory Capital Management Inc. now owns 4,569 shares of the company’s stock valued at $717,000 after acquiring an additional 464 shares in the last quarter. Finally, Aigen Investment Management LP purchased a new position in TransMedics Group during the 3rd quarter worth $523,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Piper Sandler lowered their target price on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a report on Wednesday, November 20th. JPMorgan Chase & Co. decreased their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research note on Tuesday, October 29th. Stephens boosted their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Robert W. Baird reduced their target price on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Finally, Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $80.61 on Wednesday. TransMedics Group, Inc. has a 1 year low of $67.77 and a 1 year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The business has a fifty day simple moving average of $116.21 and a two-hundred day simple moving average of $137.14. The company has a market capitalization of $2.71 billion, a P/E ratio of 85.76 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s revenue was up 63.7% compared to the same quarter last year. During the same period last year, the business posted ($0.12) EPS. On average, analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 12.27 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now directly owns 20,843 shares in the company, valued at $3,089,766.32. The trade was a 12.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,958 shares of company stock worth $3,470,328 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.